| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Medicines Company, The |
| One Cambridge Center, Cambridge, MA 02142 * (617) 225-9099 |
| Business Description | The company acquires, develops and commercializes biopharmaceutical products in late stages of development. |
| Offering Information Company has | |||
| Trading As | MDCO (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 5/19/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 8/7/00 |
| Foreign Shares Offered | 0 | Filing Range | $14.00 - $16.00 |
| Company Shares | 6,000,000 | Offer Price | $16.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.120 |
| Gross Proceeds | $96,000,000 | Selling | $0.670 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 28,200,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| J.P. Morgan & Co. | Lead Manager | (212) 648-0517 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | |
| Revenues | - | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | -1.528 | -18.465 | -30.253 | -35.353 | -8.483 | -11.690 |
| Net Income | - | -1.466 | -17.806 | -28.951 | -34.713 | -8.137 | -12.093 |
| E.P.S | - | -2.160 | -2.960 | -4.400 | -58.460 | -15.400 | -15.750 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -26.89 | -6.08 | -8.20 | ||||
| Cash Flow - Inv. | 18.54 | 3.85 | 0.52 | ||||
| Cash Flow - Fin. | 6.00 | 0.00 | 13.35 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 13.13 | Current Assets | 12.57 | Current Ratio | 0.83 |
| Total Liab. | 120.52 | Current Liab. | 15.06 | Debt Ratio | 918.26% |
| Total Equity | -107.40 | Working Cap. | -2.49 | Debt to Equity Ratio | - |
| Cash | 12.30 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund the commercial launch of Angiomax, to fund working capital, capital expenditures and other general corporate purposes and to fund the acquisition of additional products. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Hale and Dorr |
| Bank's Law Firm | Cahill Gordon & Reindel |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Warburg, Pincus Ventures, L.P. | 39.20 | |
| Biotech Growth S.A. | 24.60 | |
| Morgan Stanley Venture Partners | 9.60 | |
| Alta Partners | 9.10 | |
| PharmaBio Development, Inc. | 8.40 | |
| Hanseatic Americas LDC | 5.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||